Proton pump inhibitor therapy in gastro‐oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts

Abstract

Short-term PPI therapy in EO patients reduces the oesophageal cellular immune response, but does not change oxidative damage. PPI therapy may therefore not be effective in reducing the risk of oesophageal cancer in GERD patients.